ClinicalTrials.gg
Status unknownNCT02796261STELLARUpdated Jan 21, 2022

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

A Phase 3 interventional study of Eflornithine and Lomustine in Anaplastic Astrocytoma and Recurrent Anaplastic Astrocytoma, sponsored by Orbus Therapeutics, Inc.. Status unknown at 79 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-21.

Sponsored by Orbus Therapeutics, Inc. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Astrocytoma with a site in United States — 52 open to participants now, 81 under way, 7 of them phase 3. Astrocytoma · United States.

Enrollment
8th of 457
343 · median 30
Started
2016
with 15 others
Phase 3
26 of 553
3 open now
Registered
435th of 553
by date

Among the 553 studies in Astrocytoma with a site in United States, this one is the 8th largest by enrollment of the 457 interventional ones that give a count, is one of 16 that started in 2016, is one of 26 in phase 3, and was the 435th registered.

Astrocytoma

688 studies on the registry are indexed under Astrocytoma; 80 are open to participants now.

Browse Astrocytoma studies →

Open to participants now

52 of the 553 studies in Astrocytoma with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Astrocytoma studies recruiting now, 40 (59%) set no upper age limit and 14 (21%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Astrocytoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

Read the detailed description

This study will consist of 4 study periods of up to 50 months in total, consisting of:

Screening Period - A maximum screening duration of 4 weeks.

Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months.

End of Treatment Visit - A minimum of 4 weeks post last treatment for both arms.

Follow-Up Period - Up to approximately 36 months, or until patient death.

A total of approximately 340 patients will be randomized in a 1:1 ratio to receive either eflornithine + lomustine or lomustine alone.

03

Conditions studied

  • Anaplastic Astrocytoma
  • Recurrent Anaplastic Astrocytoma

Keywords

  • Anaplastic Astrocytoma
  • Grade 3 Glioma
  • Glioma
  • Eflornithine
  • Brain Cancer
  • Brain Tumor
  • Neuro-oncology
  • Progressive Anaplastic Astrocytoma
  • Recurrent Anaplastic Astrocytoma
  • Progressive Glioma
  • Recurrent Glioma
  • Malignant Glioma
  • Progressive Brain Tumor
  • Recurrent Brain Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for participation in this study:

  • Surgical or -proven diagnosis of WHO grade 3 AA.
  • First AA tumor progression or recurrence ≤ 6 months prior to randomization based on MRI using T2 hyperintesity, gadolinium (Gd)-contrast enhancement, or both. To avoid enrollment of patients with glioblastoma, patients with Gd-contrast enhancing tumors will be eligible if there is no necrosis seen on MRI and any of the following criteria is true:

    1. Gd-contrast lesion margins are not clearly defined,
    2. Gd-contrast lesions are only measurable in one dimension,
    3. Gd-contrast lesion has two perpendicular diameters less than 10 mm,
    4. Gd-contrast lesion has two perpendicular diameters greater than 10 mm but less than 20 mm and lesion does not demonstrate central necrosis,
    5. Recent histopathological confirmation of WHO grade 3 AA
  • Received EBRT and temozolomide chemotherapy prior to first tumor progression or recurrence of WHO Grade 3 AA.
  • Completion of EBRT ≥ 6 months prior to randomization.
  • A patient whose AA tumor has progressed or recurred and has had another surgical resection prior to randomization will be eligible if a) pathology review confirms AA, and b) post-surgical MRI demonstrates measurable tumor on T2 FLAIR.
  • Performance Status (KPS) score of ≥ 70.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following exclusion criteria are not eligible for study participation:

  • MRI defining progression is consistent with a diagnosis of glioblastoma or radiation necrosis.
  • Patients who are considered to be to EBRT and temozolomide but who have not progressed.
  • Prior systemic therapy for recurrence of AA.
  • Presence of extracranial or .
  • Prior lomustine use.
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study.
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Eflornithine + Lomustine

    Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks

    Drug: Eflornithine · Drug: Lomustine

  • Active comparator
    Lomustine

    Lomustine dosed every 6 weeks

    Drug: Lomustine

Interventions

  • Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule

    Also known as: DFMO

  • Lomustine 90 mg/m2 administered orally once every 6 weeks

    Also known as: CCNU, CeeNU, Gleostine

  • Lomustine 110 mg/m2 administered orally once every 6 weeks

    Also known as: CCNU, CeeNU, Gleostine

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: 4 years

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: 4 years

  2. Objective response rate (ORR)

    Time frame: 4 years

Other outcomes

  1. Clinical benefit response (CBR) based on magnetic resonance imaging (MRI) criteria

    Time frame: 4 years

  2. OS rate at 18 months (OS-18)

    Time frame: 18 months

  3. Relevance of OS, PFS, ORR, and CBR to commonly used molecular/genetic biomarkers obtained from most recent pre-study tumor samples

    Time frame: 4 years

  4. Pharmacokinetic Analysis - Maximum concentrations (Cmax) of eflornithine in plasma will be determined.

    Time frame: 1 Month

  5. PK - Area under the curve (AUC) of eflornithine in plasma will be determined.

    Time frame: 1 Month

07

Study locations

79 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35401, United States
  • Saint Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • University of Southern California Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • University of California Irvine Medical Center
    Orange, California 92868, United States
  • Kaiser Permanente Center
    Redwood City, California 94063, United States
  • Kaiser Permanente
    Sacramento, California 95825, United States
  • UCSD Moores Cancer Center
    San Diego, California 92093, United States
  • University of California San Francisco Medical Center
    San Francisco, California 94143, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Piedmont Physicians Neuro-Oncology
    Atlanta, Georgia 30309, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Northwestern Medicine CDH Cancer Center
    Warrenville, Illinois 60055, United States
  • The University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • Norton Cancer Institute - Louisville
    Louisville, Kentucky 40202, United States
  • Louisiana State University Health Sciences Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Scarborough, Maine 04074, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute, Brigham and Women's Hospital
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mayo Clinic Minnesota
    Rochester, Minnesota 55905, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
  • HCA Midwest Division
    Kansas City, Missouri 64132, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • JFK Medical Center
    Edison, New Jersey 08820, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University Medical Center, The Neurological Institute
    New York, New York 10032, United States
  • University of North Carolina - Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • The Cleveland Clinic, Richard E. Jacobs Health Center
    Cleveland, Ohio 44195, United States
  • OhioHealth Research and Innovation Institute
    Columbus, Ohio 43214, United States
  • Providence Brain & Spine Institute
    Portland, Oregon 97225, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina, Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Texas Oncology Austin Brain Tumor Center
    Austin, Texas 78705, United States
  • Neuro-Oncology Associates
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Swedish Health Services
    Seattle, Washington 98122, United States
  • Universitair Ziekenhuis Leuven
    Leuven, Flemish Brabant 3000, Belgium
  • Cliniques Universitaires UCL De Mont-Godinne
    Yvoir, Namur 5530, Belgium
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G2M9, Canada
  • Montreal Neurological Institute and Hospital
    Montréal, Quebec H3A 2B4, Canada
  • Institut de Cancerologie de l'Ouest - Angers
    Angers, 49055, France
  • CHRU de Brest
    Brest, 29200, France
  • Hôpital Pierre Wertheimer - Hospices Civils de Lyon
    Bron, 69500, France
  • Centre Jean Perrin
    Clermont-Ferrand, 63011, France
  • Centre Georges François Leclerc
    Dijon, 21000, France
  • Hôpital Roger Salengro
    Lille, 59037, France
  • Hôpital de la Timone
    Marseille, 13005, France
  • Hôpital Universitaire Pitié Salpêtrière
    Paris, 75013, France
  • Klinik und Poliklinik fur Neurologie der Universitat Regensburg
    Regensburg, Bayern 93053, Germany
  • Heinrich-Heine-Universitat Duesseldorf
    Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Universitätsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Fondazione IRCCS - Instituto Neurologico Carlo Besta
    Milano, 20133, Italy
  • Istituto Oncologico Veneto
    Padova, Italy
  • Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino - Ospedale Molinette
    Torino, 10126, Italy
  • Sint Elisabeth Ziekenhuis
    Tilburg, Noord-Brabant 5022 GC, Netherlands
  • Vrije Universiteit Medisch Centrum (VUMC)
    Amsterdam, Noord-Holland 1081 HV, Netherlands
  • Erasmus Medisch Centrum Daniel den Hoed
    Rotterdam, Zuid-Holland 3075 EA, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2TH, United Kingdom
  • Edinburgh Cancer Centre - Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
  • Guy's Hospital
    London, SE1 9RT, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SW3 6JJ, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Jun 2023 and a completion of Jun 2023. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2016
First posted
Jun 10, 2016
Start
Jul 2016
Primary completionEst.
Jun 2023
CompletionEst.
Jun 2023
Last update
Jan 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02796261
Lead sponsor
Orbus Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 10, 2016
Start date
Jul 2016
Primary completion
Jun 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Jan 21, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eflornithine

Start the discussion